Paracoccidioidomycosis is an endemic disease in Latin America that is rarely associated with immunosuppression and biological therapy. Herein, we report for the first time a case of pulmonary paracoccidioidomycosis reactivation after infliximab treatment. A 47-year-old man from Brazil received infliximab to treat psoriatic spondyloarthropathy and presented with cough, dyspnea, weight loss, and fever. Chest computed tomography revealed a pulmonary nodule and biopsy confirmed paracoccidioidomycosis. Treatment with sulfamethoxazole and trimethoprim was initiated for fungal infection and infliximab was reintroduced two months later. Considering his clinical improvement and favorable radiologic evolution, antifungal therapy was discontinued after 29 months.
INTRODUCTION
Paracoccidioidomycosis (PCM) is a systemic mycosis with dragged evolution caused by the fungus Paracoccidioides sp., which is endemic in regions of Latin America. The infection occurs through inhalation of the fungus during activities related to soil management. Infected individuals can remain asymptomatic or develop acute PCM. Additionally, throughout life, quiescent lesions may be reactivated (a clinical condition known as the chronic adult form) or the residual form may develop, mainly characterized by the formation of fibrotic sequelae [1] [2] [3] . Smoking and alcoholism behaviors have been associated as potential factors for PCM reactivation [1] [2] [3] . In addition, immunosuppressive diseases or medications may also play a role in disease progression 4, 5 .
Anti-tumor necrosis factor alpha (anti-TNF-α) inhibitors are drugs administered to treat auto-immune and auto-inflammatory diseases. These drugs are now widely administered to effectively reduce inflammation [4] [5] [6] [7] . On the other hand, the use of anti-TNF-α therapy has been associated with an increased risk of severe opportunistic infections, as well as tuberculosis and histoplasmosis. In addition, infections such as aspergillosis, candidiasis, bartonellosis, legionellosis, listeriosis, leprosy, non-tuberculous mycobacterial infections, and others have been associated with anti-TNF-α [5] [6] [7] .
Despite the few reports describing the association between biological therapy and reactivation of PCM, none of them described a correlation between the use of infliximab to reactivation of the disease 4, [8] [9] [10] . Thus, this report presents a case of pulmonary PCM reactivation in a patient receiving infliximab therapy.
CASE REPORT
A 47-year-old man from Espírito Santo, Southeastern Brazil, who was a non-smoker and non-alcoholic with a past history of engaging in soil-related activities, presented with recurrent bilateral uveitis since 2007, associated with lower back pain, calcaneodynia, and inflammatory cutaneous lesions in the knees and elbows, consistent with signs of psoriasis. In 2010, he was diagnosed with psoriatic spondyloarthritis. He was initially administered methotrexate (20mg/week) after negative screening results for tuberculosis (negative tuberculin skin test results and normal chest radiography). After four months, the treatment was suspended due to gastrointestinal intolerance and remission of disease symptoms.
However, in 2013, he presented uveitis reactivation with a reduction in visual acuity and associated arthritis in the knee. He received a new cycle of prednisone, and azathioprine administration was initiated (2mg/kg/day), followed by a gradual reduction of the systemic corticosteroid. Azathioprine was substituted by infl iximab after 20 days because of the development of febrile neutropenia.
After new negative tuberculosis screening results (negative tuberculin skin test results and normal chest radiography), 11 infusions of infl iximab (0.5mg/kg) were administered for 18 months. Nevertheless, in December 2014, the patient presented with dry cough, dyspnea, arthralgia, weight loss, fever, and sweating. On examination, he was pallid and eupneic, and exhibited decreased breath sounds in the lung bases and sparse rales without cardiovascular or abdominal changes. Chest computed tomography (CT) showed a nodule with soft-tissue density of undetermined nature in the lower lobe of the left lung associated with mediastinal and perihilar lymphadenopathy, and cortical micronodules, all smaller than 5mm, which were more numerous in the left lung (Figure 1) .
Mediastinoscopy with lymph node biopsy was inconclusive and showed negative results for acid-alcohol-resistant bacillus (BAAR) and fungi. Infl iximab treatment was suspended until the defi nition of the pulmonary condition was fulfi lled. After suspension of the immunosuppressive therapy, the patient progressed with general clinical and respiratory improvements. However, chest CT still showed a nodule with soft-tissue density in the lower lobe of the left lung measuring approximately 10mm and perihilar ganglia calcifi cations. Thus, in 2015, segmentectomy of the left inferior pulmonary lobe (pulmonary nodule site) and periaortic lymph node biopsy were performed. Histopathologic results of segmentectomy revealed chronic granulomatous inflammation, with rounded structures of varying sizes and lateral budding forms compatible with those of Paracoccidioides sp. (Figure 2) . The mediastinal lymph node biopsy showed chronic granulomatous infl ammation in areas of central fi brosclerosis and negative results for BAAR and fungi.
The treatment for PCM was initiated with 800mg of sulfamethoxazole plus 160mg of trimethoprim twice a day. Detection of anti-Paracoccidioides brasiliensis, and antiAspergillus and anti-Histoplasma antibodies, using the double immunodiffusion method, was negative at the beginning of the treatment and during the follow-up. After two months, due to favorable clinical evolution, infl iximab was reintroduced (5mg/kg every six weeks). After 29 months of PCM treatment, new control chest CT showed a fi brous and calcifi ed band in the lower lobe of the left lung besides persisting calcifi ed hilar ganglia and mediastinal lymphadenopathy. Based on the residual aspect of the lesions observed using control CT and clinical improvement of the patient, the treatment for PCM was discontinued and clinical follow-up was maintained. Currently, the patient is undergoing regular treatment for psoriatic arthritis with infl iximab.
DISCUSSION
TNF-α is a pro-inflammatory cytokine critical for the formation and maintenance of the granuloma. This cytokine also mediates immune protection against intracellular pathogens and has a central role in the pathogenesis of auto-immune and auto-infl ammatory diseases. Therefore, the administration of anti-TNF-α therapy has been shown to be an effective tool to treat these diseases 7 .
However, TNF-α inhibitors have been associated with an increased risk of developing opportunistic infections [4] [5] [6] [7] . A systematic review and meta-analysis involving 5,014 randomized patients who received infliximab, adalimumab, or placebo concluded that anti-TNF-α therapy increases the risk of infection when compared with placebo (odds ratio 2.0; 95% confidence interval 1.3-3.1)
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The association between PCM and the use of immunosuppressive drugs has already been described in the literature, but until now, there have been no reports on disease reactivation after infliximab administration. Most of the 11 cases previously described were in men aged older than 40 years with pulmonary involvement (Table 1) 4, [8] [9] [10] .
The reported case is suggestive of PCM's chronic form due to the pattern of nodular and micronodular lesions involving both lungs. Brazil has the largest number of PCM cases in Latin America, and southeast Brazil, including Espírito Santo State, is considered a high endemic area 12 . Despite this, there is insufficient PCM screening, enabling the reactivation of latent infections after immunosuppression therapy.
Currently, the interruption of anti-TNF-α therapy is proposed if a fungal infection has been diagnosed during treatment 6 .
In this case report, the only associated risk factor for disease reactivation was the administration of immunosuppressive drugs: mainly the association of infliximab and prednisone. These were discontinued when the definition of the pulmonary condition was fulfilled and reintroduced after clinical and radiologic improvement with antifungal therapy. Although there are no clinical protocols to support the management of these patients, the conduct described here allowed for successful outcomes.
The reported case warns about the importance of suspecting PCM in patients with respiratory symptoms undergoing biological therapy, mainly in those from endemic areas.
